Research location
Sochaczew
Masovian Voivodeship, Poland
Advertisement
Research activity in Sochaczew
Masovian Voivodeship, PolandCureCurrent currently publishes aggregate city-level research activity for this location: 8 trials and 8 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Sochaczew
8 linked trials · page 1 of 1Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease DementiaNCT07284472 · 2026-02-02 · 1 site observation
RECRUITING
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPDNCT06981078 · 2025-07-02 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Medical Cannabis Aerosol Via the Fixed-dose Syqe Inhaler as an Add-on Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)NCT06490445 · 2024-11-14 · 1 site observation
COMPLETED
A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PDNCT05357989 · 2022-08-03 · 1 site observation
COMPLETED
MSB11456 in Participants With Moderately to Severely Active Rheumatoid ArthritisNCT04512001 · 2020-08-03 · 1 site observation
COMPLETED
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeNCT04408755 · 2020-07-13 · 1 site observation
TERMINATED
PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706NCT03655236 · 2019-02-18 · 1 site observation
TERMINATED
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeNCT02446132 · 2015-11-13 · 1 site observation
TERMINATED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.